Change in bronchial hyper-reactivity as a doubling dilution shift for formoterol and salmeterol in genotype-specific patients as change from placebo after chronic dosing
| Doubling dilution (dd) shift | ||||
| Drug | Genotype | >1 dd (improvement) | ±1 dd (no change) | >1 dd (worsening) |
| Formoterol | Arg-Arg and Arg-Gly | 17% | 23% | 60% |
| Gly-Gly | 27% | 44% | 29% | |
| Salmeterol | Arg-Arg and Arg-Gly | 35% | 46% | 18% |
| Gly-Gly | 50% | 39% | 11% | |
After data from Lee et al.5
After data from Lee et al.5